An established drug for recurrent multiple myeloma might effectively be repurposed to improve the survival and day-to-day lives of patients with devastating sickle cell disease, according to revealing new research by a Feinstein Institute for Medical Research scientist.
The study, by Lionel Blanc, PhD, an assistant investigator at the Feinstein Institute, will be published Dec. 17 in the journal Blood. Dr. Blanc’s research, performed in collaboration with the New York Blood Center, Yale School of Medicine and University of Montpellier in France, was the first to identify how the drug pomalidomide increases production of fetal hemoglobin, known to interfere with the so-called “sickling” of red blood cells implicated in sickle cell disease (SCD).
Illuminating pomalidomide’s mechanism of action offers proof of concept that the US Food and Drug Administration (FDA)-approved medication could potentially be used to treat SCD, representing better outcomes compared to current drug treatment for the 100,000 Americans with SCD, an inherited disorder causing poor oxygen delivery, organ damage and even death.
“We knew the drug would make fetal hemoglobin, but we didn’t know to what extent or how. That was the goal of the study,” explained Dr. Blanc, also an assistant professor of molecular medicine and pediatrics at Hofstra North Shore-LIJ School of Medicine and an Allied World St. Baldrick’s Scholar.
“We can also say something else – that hydroxyurea, the only FDA-approved drug for sickle cell anemia, was less effective than pomalidomide and appeared to act through a different mechanism of action,” he added. “The current therapy is good, but not everyone responds equally to hydroxyurea, and what we hope with pomalidomide is to improve this.”
Pomalidomide, a derivative of thalidomide used in advanced cases of the cancer multiple myeloma, works by killing malignant plasma cells. But Dr. Blanc and his colleagues demonstrated in the new research, performed on stem cells taken from five SCD patients and 120 normal controls, how pomalidomide also generated fetal hemoglobin, the fetal version of the protein in red blood cells that carries oxygen to body tissues.
In patients with congenital conditions producing anemia such as SCD and beta-thalassemia, fetal hemoglobin is normal, but adult hemoglobin – produced after birth – is abnormal. Therefore, reversing their production of adult hemoglobin back to fetal hemoglobin can reverse the course of their disease.
In addition to the 100,000 US residents with SCD, the condition also affects millions globally. “I would remind people that anemia impacts 1.6 billion people worldwide, making it a global economic burden,” Dr. Blanc notes.
Dr. Blanc and his colleagues in the Division of Hematology/Oncology at Cohen Children’s Medical Center of New York plan to launch a clinical trial in the near future in collaboration with other institutions to test pomalidomide, which is taken orally, in young adults with SCD.
Currently, the only potential cures for SCD are gene therapy, still in the experimental stage, or stem cell transplant, but these resource-intense treatments aren’t available to the vast majority of patients, particularly in the developing world.
“Our hope is to alleviate the symptoms of sickle cell disease by using a pill that could be made available to almost all patients, worldwide,” Dr. Blanc said.
The Latest on: Sickle Cell Disease
via Google News
The Latest on: Sickle Cell Disease
- Revolutionary Treatment for Sickle Cell Disease Shows Promise in Clinical Trialon January 16, 2020 at 12:53 pm
Sickle cell disease is the most common red blood cell disorder in the United States, having been diagnosed in approximately 100,000 African Americans alone. The lack of oxygen from sickle cell buildup ...
- Managing Sickle Cell Disease: Innovations, Limitations Within Evolving Standards of Careon January 15, 2020 at 5:47 pm
In the evolving treatment landscape for sickle cell disease, current standards of treatment involve 4 drugs that have been FDA approved, with further innovations and limitations adding to the paradigm ...
- Local SC sickle cell nonprofit pushes for more disease awarenesson January 15, 2020 at 3:27 pm
Brenda Green had no idea what sickle cell anemia was when her 13-year-old son Braden was diagnosed with it at 3 months. After a newborn screening test determined he had the disease, she and her ...
- Sickle Cell Disease Drug Market Analysis with Size, Manufacturers, Applications and Forecast Research Reporton January 15, 2020 at 6:49 am
Jan 15, 2020 (Market Prediction via COMTEX) -- Ameco Research Presents “Global Sickle Cell Disease Drug Market Research Report 2019” New Document to its Studies Database. The Report Contain 121 Pages ...
- Sickle Cell Disease: A Primer for Primary Care Providerson January 14, 2020 at 3:28 pm
Sickle cell disease is an autosomal recessive disorder with significant global impact. This disorder causes the production of a dysfunctional hemoglobin, which leads to sickling of erythrocytes and ...
- At 16, She’s a Pioneer in the Fight to Cure Sickle Cell Diseaseon January 11, 2020 at 12:47 pm
Helen Obando is the youngest person ever to get a gene therapy that scientists hope will cure the disease, which afflicts 100,000 Americans. BOSTON — Helen Obando, a shy slip of a girl, lay curled in ...
- A Teenager’s Breakthrough Gene Therapy for Sickle Cell Diseaseon January 11, 2020 at 11:01 am
Doctors reset Helen Obando’s DNA in an effort to cure her of a painful genetic blood disorder. She’s the youngest person to receive the treatment.
- At 16, she’s a pioneer in the fight to cure sickle cell disease at Boston Children’son January 11, 2020 at 9:57 am
The hope was that the treatment would cure her of sickle cell disease, an inherited blood disorder that can cause excruciating pain, organ damage and early death. Helen, who at 16 was the youngest ...
- FDA grants rare pediatric disease designation to gene therapy for sickle cell diseaseon January 10, 2020 at 9:54 am
The FDA granted rare pediatric disease designation to ARU-1801, an investigational autologous gene therapy, for the treatment of sickle cell disease, according to the agent’s manufacturer. ARU-1801 ...
- Gene therapy to boost fetal hemoglobin continues to do well in sickle cell trialon January 10, 2020 at 5:50 am
A pilot gene therapy treatment for sickle cell disease, restoring patients' ability to make fetal hemoglobin, has produced good results in the first three patients to receive it. Investigators at ...
via Bing News